TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34016544

Group type: EXPERIMENTAL
Intervention: 5‐item dry eye questionnaire (DEQ‐5)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index (OSDI)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: McMonnies Dry Eye Questionnaire (MQ)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ocular Comfort Index questionnaires (OCI)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: DEQ
Number of subjects: 113
Study: 34610929

Group type: EXPERIMENTAL
Intervention: 12-week home-based combined resistance and aerobic exercise intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 50
Study: 36093860

Group type: EXPERIMENTAL
Intervention: Virtual embodiment (VE) using an older avatar
Number of subjects: 80

Group type: COMPARATOR
Intervention: Virtual embodiment (VE) using a younger avatar
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (younger avatar)
Number of subjects: 80
Study: 33004472

Group type: EXPERIMENTAL
Intervention: empagliflozin (25 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY2409021 (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: empagliflozin + LY2409021
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY2409021
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 35143872

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 35 mg orally twice a day for 3 months
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 5 mg/kg solution every two days by gavage for two weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (conventional treatments)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Model group (D-gal 500 mg/kg intraperitoneal injection every two days for six weeks)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 53
Study: 34396584

Group type: EXPERIMENTAL
Intervention: 10 mL lidocaine (2%)
Number of subjects: 8
Study: 36050587

Group type: EXPERIMENTAL
Intervention: Online group problem-solving therapy (PST)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 55
Study: 32737435

Group type: EXPERIMENTAL
Intervention: Passive smoking frequency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tea consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal alcohol intake frequency ≥ 1/week
Number of subjects: 0
Study: 36049147

Group type: EXPERIMENTAL
Intervention: encorafenib (450 mg orally once daily) plus binimetinib (45 mg orally twice daily) until progressive disease -> ipilimumab plus nivolumab (ipilimumab 3 mg/kg once every 3 weeks and nivolumab 1 mg/kg once every 3 weeks × four cycles -> nivolumab 3 mg/kg every 2 weeks)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: ipilimumab plus nivolumab until progressive disease -> encorafenib plus binimetinib
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: encorafenib plus binimetinib for 8 weeks -> ipilimumab plus nivolumab until progressive disease -> encorafenib plus binimetinib
Number of subjects: 209
Study: 33455924

Group type: EXPERIMENTAL
Intervention: Any depression
Number of subjects: 9856

Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 9856

Group type: EXPERIMENTAL
Intervention: Age, maternal education, paternal occupation, household factors, physical activity, television viewing time
Number of subjects: 9856

Group type: EXPERIMENTAL
Intervention: Paternal education, household composition, fuel use, tobacco use, processed food consumption (boys only)
Number of subjects: 9856

Group type: EXPERIMENTAL
Intervention: Non-slum urban residence, Muslim religion, household size (girls only)
Number of subjects: 9856
Study: 33357217

Group type: EXPERIMENTAL
Intervention: Edoxaban (a direct oral anticoagulant)
Number of subjects: 20867

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 20867

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 20867

Group type: EXPERIMENTAL
Intervention: Frailty index increase (0.1 increase)
Number of subjects: 20867
Study: 34246993

Group type: EXPERIMENTAL
Intervention: SaO2 <93%
Number of subjects: 11093

Group type: EXPERIMENTAL
Intervention: SaO2 levels outside of 96–97%
Number of subjects: 11093
Study: 32712569

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 36498427

Group type: EXPERIMENTAL
Intervention: Coaching-based teleoccupational guidance (CTG) over 3 months via WeChat
Number of subjects: 25

Group type: COMPARATOR
Intervention: Routine teleoccupational guidance (RTG)
Number of subjects: 25
Study: 32719097

Group type: EXPERIMENTAL
Intervention: Device that narrows the coronary sinus
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sham implantation
Number of subjects: 104
Study: 32861085

Group type: EXPERIMENTAL
Intervention: TV viewing time
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Computer, iPad, Phone usage
Number of subjects: 2278
Study: 35941676

Group type: EXPERIMENTAL
Intervention: Infliximab 5mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34315974

Group type: EXPERIMENTAL
Intervention: Support vector machine with a radial basis function kernel
Number of subjects: 488
Study: 32636043

Group type: EXPERIMENTAL
Intervention: Early mobilization (E-MOB) with a removable orthosis and daily wrist exercises
Number of subjects: 95

Group type: COMPARATOR
Intervention: Late mobilization (L-MOB) with a standard dorsal plaster cast for 2 weeks followed by a removable orthosis and exercises
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Early mobilization (E-MOB)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Late mobilization (L-MOB)
Number of subjects: 95
Study: 35016497

Group type: EXPERIMENTAL
Intervention: TRLB (0.25% bupivacaine 0.4 ml/kg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 66
Study: 33650105

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic (NLC) visits
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Nurse-led clinic (NLC) visits at 2 months only
Number of subjects: 656
Study: 32488902

Group type: EXPERIMENTAL
Intervention: Nitrogen-containing bisphosphonates (N-BPs)
Number of subjects: 4041
Study: 34233985

Group type: EXPERIMENTAL
Intervention: Active intermittent theta burst stimulation (iTBS) to the right temporoparietal junction (rTPJ), 600 pulses, 20 sessions over 4 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS) to the right temporoparietal junction (rTPJ), mimicking the sensation of iTBS without active stimulation
Number of subjects: 150
Study: 33900249

Group type: EXPERIMENTAL
Intervention: Upright position during heelstick
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Supine on the lap during heelstick
Number of subjects: 90

Group type: COMPARATOR
Intervention: Supine on the crib (control group) during heelstick
Number of subjects: 90
Study: 32078147

Group type: EXPERIMENTAL
Intervention: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 11.5 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intramuscular clodronate 200 mg daily for 15 days and then once weekly for the next 2.5 months
Number of subjects: 74
Study: 34984679

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 53452

Group type: COMPARATOR
Intervention: Chest x-ray (CXR) screening
Number of subjects: 53452
Study: 33373914

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol (IPA) inhalation
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (P) inhalation
Number of subjects: 118
Study: 32087425

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study: 32185991

Group type: EXPERIMENTAL
Intervention: ZiYin Xiehuo granules (ZYXH)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Zishen Qinggan granules (ZSQG)
Number of subjects: 143
Study: 35556138

Group type: EXPERIMENTAL
Intervention: M-ECT
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 60
Study: 32653912

Group type: EXPERIMENTAL
Intervention: Access to managed aquifer recharge (MAR) water
Number of subjects: 5745

Group type: COMPARATOR
Intervention: No access to managed aquifer recharge (MAR) water
Number of subjects: 5745
Study: 32647106

Group type: EXPERIMENTAL
Intervention: Mixed reality (MR) technology assisted lumbar pedicle screws placement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional lumbar pedicle screws placement
Number of subjects: 50
Study: 35134897

Group type: EXPERIMENTAL
Intervention: MitraClip plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study: 35717867

Group type: EXPERIMENTAL
Intervention: MR stimulation (0.4 mg fludrocortisone)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: NMDA-R stimulation (250 mg D-cycloserine)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combined MR/NMDA-R stimulation
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 32437396

Group type: EXPERIMENTAL
Intervention: Knowledgeable informants
Number of subjects: 90

Group type: COMPARATOR
Intervention: Randomly selected informants
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: General perception
Number of subjects: 90
Study: 35137532

Group type: EXPERIMENTAL
Intervention: RD-X19
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 31
Study: 33963372

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg per day)
Number of subjects: 12705

Group type: COMPARATOR
Intervention: Blood pressure lowering treatment
Number of subjects: 12705
Study: 32821078

Group type: EXPERIMENTAL
Intervention: Biling Weitong Granules (BLWTG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34347136

Group type: EXPERIMENTAL
Intervention: PIDENT scoring model for predicting non-diagnostic evaluation of DES-ISR
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Baseline characteristics including implanted stent diameter, severe calcification, stent-in-stent lesion, and type of DES
Number of subjects: 757

Group type: COMPARATOR
Intervention: Non-diagnostic evaluation of DES
Number of subjects: 757
Study: 32628547

Group type: EXPERIMENTAL
Intervention: Morphine Treatment with Metoclopramide Coadministration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine Treatment without Metoclopramide Coadministration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35590182

Group type: EXPERIMENTAL
Intervention: Alcohol responsibility messages with modified content (direct language and consequence)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Alcohol responsibility messages with variances in type size or type contrast
Number of subjects: 121
Study: 32444343

Group type: EXPERIMENTAL
Intervention: HIIE (High-Intensity Interval Exercise): cycling for 4×4 min at 85%-95% of heart rate peak (HRpeak), interspersed with 3 min of active recovery at 60%-70% HRpeak
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MICE (Moderate-Intensity Continuous Exercise): 33 min of continuous cycling at 60%-70% HRpeak
Number of subjects: 24

Group type: COMPARATOR
Intervention: CON (Control): lying quietly in a supine position for 30 min
Number of subjects: 24
Study: 36370162

Group type: EXPERIMENTAL
Intervention: Decon group (step-wise teaching with educational videos)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Trad group (traditional method with continuous demonstration)
Number of subjects: 64
Study: 33804824

Group type: EXPERIMENTAL
Intervention: Field IBV strains
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vaccine IBV strains
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: IBV genome sequences
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Recombination hot spots
Number of subjects: 69
Study: 32865229

Group type: EXPERIMENTAL
Intervention: Higher emotion knowledge (EK) at the end of pre-K
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Emotion knowledge (EK) interventions and strategies in pre-K programs
Number of subjects: 1050
Study: 34463630

Group type: EXPERIMENTAL
Intervention: Noom app user group (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-Noom user group (n=20)
Number of subjects: 40
Study: 32507432

Group type: EXPERIMENTAL
Intervention: Craniofacial massage (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 35212802

Group type: EXPERIMENTAL
Intervention: Bioresorbable-polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Durable-polymer everolimus-eluting stent (DP-EES)
Number of subjects: 2350

Group type: EXPERIMENTAL
Intervention: Complex PCI
Number of subjects: 2350

Group type: COMPARATOR
Intervention: Non-complex PCI
Number of subjects: 2350
Study: 36455453

Group type: EXPERIMENTAL
Intervention: PEA‐LUT 700 mg + 70 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: PLACEBO
Number of subjects: 39
Study: 33994141

Group type: EXPERIMENTAL
Intervention: Emergency feeding services during the COVID-19 pandemic
Number of subjects: 34
Study: 32938462

Group type: EXPERIMENTAL
Intervention: Community-based health insurance (CBHI) uptake
Number of subjects: 845

Group type: EXPERIMENTAL
Intervention: Willingness to pay for CBHI
Number of subjects: 845
Study: 35488222

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise programme (3 sessions per week of moderate-intensity aerobic exercise using a cycle ergometer)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 12-week aerobic exercise programme
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 34183431

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4304
Study: 36259143

Group type: EXPERIMENTAL
Intervention: eTansiyon smartphone application
Number of subjects: 185
Study: 33994233

Group type: EXPERIMENTAL
Intervention: Nonintubated thoracoscopic lobectomy
Number of subjects: 252

Group type: COMPARATOR
Intervention: Intubated thoracoscopic lobectomy
Number of subjects: 252
Study: 32210289

Group type: EXPERIMENTAL
Intervention: Semi-automated detection algorithm for CIED infections
Number of subjects: 5703

Group type: COMPARATOR
Intervention: Manual review of CIED procedures
Number of subjects: 5703
Study: 35345936

Group type: EXPERIMENTAL
Intervention: 6-week education program consisting of 6 sessions
Number of subjects: 138

Group type: COMPARATOR
Intervention: No educational intervention (Control)
Number of subjects: 138
Study: 33570158

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) program, 5 days a week, once a day, for 8 weeks, with progressive intensity from 15% to 60% of PImax.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group performing the same program with a fixed load of 7cmH20.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experimental group (IMT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (IMT and placebo)
Number of subjects: 16
Study: 34992123

Group type: EXPERIMENTAL
Intervention: Treatment of venous leg ulcers with community staff involvement
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Use of antimicrobial dressings
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Wound care delivered in the home
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: National cost of treating venous leg ulcers
Number of subjects: 9
Study: 34399166

Group type: EXPERIMENTAL
Intervention: eNose analysis for early monitoring during anti-PD-1 therapy
Number of subjects: 94
Study: 36114831

Group type: EXPERIMENTAL
Intervention: RAM cannula
Number of subjects: 254

Group type: COMPARATOR
Intervention: Short binasal prongs (SBP)
Number of subjects: 254
Study: 33750646

Group type: EXPERIMENTAL
Intervention: SPN-812 200 mg
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: SPN-812 400 mg
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 36395192

Group type: EXPERIMENTAL
Intervention: 30 minutes of balance training followed by 1 hour and 30 minutes of ordinary badminton training, 2 days per week for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: 2 hours of ordinary badminton training
Number of subjects: 20
Study: 33846037

Group type: EXPERIMENTAL
Intervention: High-intensity follow-up (examinations at 6, 12, 18, 24, and 36 months)
Number of subjects: 2509

Group type: COMPARATOR
Intervention: Low-intensity follow-up (examinations at 12 and 36 months)
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Elevated CEA levels before treatment
Number of subjects: 2509

Group type: EXPERIMENTAL
Intervention: Elevated CEA levels after surgery
Number of subjects: 2509
Study: 34183458

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention in polypharmacy patients
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention in patients aged >60 years
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational intervention in patients with high education level
Number of subjects: 89
Study: 32692247

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) alone 300 cGy/fraction ×10 fractions, total dose 3,000 cGy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT) alone 180 cGy/fraction ×22 fractions, total dose 3,960 cGy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intracranial metastases radiotherapy alone 250 cGy/fraction ×22 fractions, total dose 5,500 cGy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whole brain + intracranial metastases group (SIB) whole brain 180 cGy/fraction ×22 fractions, intracranial metastases 250 cGy/fraction ×22 fractions, total doses 3,960 cGy and 5,500 cGy respectively
Number of subjects: 80

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whole brain + intracranial metastases group (SIB)
Number of subjects: 80
Study: 36386372

Group type: EXPERIMENTAL
Intervention: MUSKARDIA
Number of subjects: 776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 776
Study: 32233902

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (atDCS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study: 35411785

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 3699

Group type: COMPARATOR
Intervention: Control (non-invasive strategy)
Number of subjects: 3699
Study: 34052007

Group type: EXPERIMENTAL
Intervention: Ivermectin (0.2 mg/kg single dose)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 69
Study: 32579810

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 35621233

Group type: EXPERIMENTAL
Intervention: Same-Day Discharge (SDD) after TAVI
Number of subjects: 158591

Group type: COMPARATOR
Intervention: Next-Day Discharge after TAVI
Number of subjects: 158591

Group type: COMPARATOR
Intervention: Second or Third Day Discharge after TAVI
Number of subjects: 158591

Group type: COMPARATOR
Intervention: Non-Same-Day Discharge (Non-SDD) after TAVI
Number of subjects: 158591
Study: 34912021

Group type: EXPERIMENTAL
Intervention: Split tablet regimen (group S)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Alternate-day regimen (group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups (S and A)
Number of subjects: 66
Study: 34262120

Group type: EXPERIMENTAL
Intervention: Vestibular exercise (VE) for 20 min using a virtual reality system once a week for 4 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Vestibular exercise (VE) for 20 min using a virtual reality system once a week for 4 weeks + optokinetic stimulation (OS) for 9 min
Number of subjects: 28
Study: 34544754

Group type: EXPERIMENTAL
Intervention: Combination of erector spinae block and retrolaminar block (10 mL each)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Erector spinae block (20 mL)
Number of subjects: 8
Study: 36243227

Group type: EXPERIMENTAL
Intervention: Direct consultations with medical physicists during treatment simulation and before the first treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct consultations with medical physicists.
Number of subjects: 0
Study: 33726983

Group type: EXPERIMENTAL
Intervention: 12th grade letter
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: 12th grade infographic
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: 6th grade infographic
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: 6th grade letter
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Indirect understanding of abnormal test results
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 909
Study: 35990583

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily by mouth in 21-day cycles)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 70
Study: 34983471

Group type: EXPERIMENTAL
Intervention: Viscosupplementation (single-dose intraarticular hyaluronic acid injection)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no viscosupplementation)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Viscosupplementation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control
Number of subjects: 47
Study: 34480134

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PGGRS) calculated using 13 SNPs
Number of subjects: 4592

Group type: COMPARATOR
Intervention: Models without PGGRS (Cox, ANN, RF, GBM)
Number of subjects: 4592

Group type: EXPERIMENTAL
Intervention: Models with PGGRS (Cox, ANN, RF, GBM)
Number of subjects: 4592
Study: 35395598

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (n=8)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Resistance exercise program (n=6)
Number of subjects: 14
Study: 32069192

Group type: EXPERIMENTAL
Intervention: Transgender heterosexual female defendants
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cisgender gay male defendants
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All defendants
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Transgender defendants
Number of subjects: 300